We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Gsk Plc | LSE:GSK | London | Ordinary Share | GB00BN7SWP63 | ORD 31 1/4P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1,810.00 | 1,811.00 | 1,812.00 | 1,812.50 | 1,797.00 | 1,805.00 | 4,741,076 | 16:35:16 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 30.33B | 4.93B | 1.1970 | 15.13 | 74.58B |
From May 2019 to May 2024
By Cecilia Butini
GlaxoSmithKline PLC and Novavax Inc. said Monday that the two companies have reached an agreement in principle with the U.K. government to support the manufacturing of Novavax's coronavirus vaccine in the U.K.
Glaxo, a British pharmaceutical company, said it will provide fill-and-finish manufacturing capacity at its Barnard Castle facility in England starting in May 2021. Fill and finish is understood as the final stage of vaccine manufacturing, where vials are prepared and packaged for distribution.
A "rapid" technology transfer between Glaxo and U.S. pharmaceutical giant Novavax will begin immediately, the companies said.
The U.K. government has secured 60 million vaccine doses under an advance-purchase agreement with Novavax.
Write to Cecilia Butini at cecilia.butini@wsj.com
(END) Dow Jones Newswires
March 29, 2021 13:08 ET (17:08 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
1 Year Gsk Chart |
1 Month Gsk Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
